Andrographis and colds

What 2 graded rows on andrographis agree on for colds, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Andrographis page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Andrographis page, with its PubMed record.

Supplement

Andrographis Choose another

2 rows · 7,475 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a meta-analysis of 7,175 people (2017) and found an improvement.

The rows run from 300 to 7,175 people, published from 2017 to 2023: 1 pooled review and 1 single study.

2 improved

Grade CSymptoms of acute respiratory tract infections · Improved
Meta-analysis · n 7,175 · 2017 · Adults and children with acute respiratory tract infections in 33 RCTs (English and Chinese databases)
Varied by trial · Days
Cough (SMD -0.39, 95% CI -0.67 to -0.10; n = 596) and sore throat (SMD -1.13, 95% CI -1.37 to -0.89; n = 314) improved versus placebo; overall symptoms and time to resolution also improved. Minor side effects were mainly gastrointestinal.
Row on the Andrographis page · PubMed 28783743 (opens PubMed)
Grade CCommon cold symptom score (WURSS-21) · Improved
RCT · n 300 · 2023 · Adults with uncomplicated upper respiratory tract viral infection (common cold)
200 or 400 mg/day · 7 days
Both doses gave lower symptom scores than placebo on day 3 (about 3.8 points), but not on days 5 and 7; nasal mucus weight and IL-8 did not differ significantly. No adverse symptoms were reported.
Row on the Andrographis page · PubMed 36842634 (opens PubMed)